Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study Assessing the Ability of an Ex-vivo Assay to Measure AMD3100's Ability to Overcome Tumour Immune-privilege and Bring T-lymphocytes Into Contact With Neoplastic Targets.

NCT02695966 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT02695966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02695966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study Assessing the Ability of an Ex-vivo Assay to Measure AMD3100's Ability to Overcome Tumour Immune-privilege and Bring T-lymphocytes Into Contact With Neoplastic Targets.
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Phase
Observational
Overall status
Completed
Start date
May 31, 2015
Completion date
July 31, 2018
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer